PL2395990T3 - Materiał leczniczy i sposoby leczenia zaburzeń rozwojowych, w tym autyzmu współistniejącego i autyzmu idiopatycznego - Google Patents

Materiał leczniczy i sposoby leczenia zaburzeń rozwojowych, w tym autyzmu współistniejącego i autyzmu idiopatycznego

Info

Publication number
PL2395990T3
PL2395990T3 PL10705949T PL10705949T PL2395990T3 PL 2395990 T3 PL2395990 T3 PL 2395990T3 PL 10705949 T PL10705949 T PL 10705949T PL 10705949 T PL10705949 T PL 10705949T PL 2395990 T3 PL2395990 T3 PL 2395990T3
Authority
PL
Poland
Prior art keywords
methods
disorders including
developmental disorders
treating developmental
idiopathic autism
Prior art date
Application number
PL10705949T
Other languages
English (en)
Inventor
Craig A Erickson
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of PL2395990T3 publication Critical patent/PL2395990T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10705949T 2009-02-12 2010-02-12 Materiał leczniczy i sposoby leczenia zaburzeń rozwojowych, w tym autyzmu współistniejącego i autyzmu idiopatycznego PL2395990T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15185809P 2009-02-12 2009-02-12
EP10705949.5A EP2395990B1 (en) 2009-02-12 2010-02-12 Material and methods for treating developmental disorders including comorbid and idiopathic autism
PCT/US2010/024008 WO2010093859A1 (en) 2009-02-12 2010-02-12 Material and methods for treating developmental disorders including comorbid and idiopathic autism

Publications (1)

Publication Number Publication Date
PL2395990T3 true PL2395990T3 (pl) 2015-04-30

Family

ID=42103866

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10705949T PL2395990T3 (pl) 2009-02-12 2010-02-12 Materiał leczniczy i sposoby leczenia zaburzeń rozwojowych, w tym autyzmu współistniejącego i autyzmu idiopatycznego

Country Status (12)

Country Link
US (2) US9463172B2 (pl)
EP (1) EP2395990B1 (pl)
JP (1) JP5688035B2 (pl)
AU (1) AU2010213683B2 (pl)
CA (1) CA2781830C (pl)
DK (1) DK2395990T3 (pl)
ES (1) ES2530047T3 (pl)
HR (1) HRP20150120T1 (pl)
PL (1) PL2395990T3 (pl)
PT (1) PT2395990E (pl)
SI (1) SI2395990T1 (pl)
WO (1) WO2010093859A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110294879A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20130296430A1 (en) * 2012-05-03 2013-11-07 Antonio Hardan Compositions and methods for treating autism and autism spectrum disorder
CA2879113C (en) * 2012-07-22 2021-11-16 Indiana University Research And Technology Corporation Modulation sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
RU2696481C2 (ru) 2013-10-14 2019-08-02 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Применение акампросата для модулирования активации erk1/2 в животных моделях fxs и asd и людей с диагностированными fxs и asd
WO2016132136A1 (en) 2015-02-18 2016-08-25 Aston University Diagnostic assay and treatment for preeclampsia
KR102790656B1 (ko) 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
WO2017024129A1 (en) * 2015-08-04 2017-02-09 Confluence Pharmaceuticals, Llc Combination therapy using acamprosate and d-cycloserine
IL270654B2 (en) 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602150A (en) 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
DE60214846T2 (de) * 2001-04-02 2007-05-16 Brown University Research Foundation Verwendung von mGLuR5 antagonists zur Herstellung von Medikamenten zur Behandlung von empfindlichen X Syndrome, Autismus und geistiger Zurückgebliebenheit
DE10129265A1 (de) 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
ES2564187T3 (es) 2005-04-05 2016-03-18 Yale University Agentes de modulación de glutamato en el tratamiento de trastornos mentales
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
AU2008204800A1 (en) 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US20100317715A1 (en) 2007-12-21 2010-12-16 Vollrath Benedikt Methods for treating neuropsychiatric conditions

Also Published As

Publication number Publication date
AU2010213683B2 (en) 2016-04-21
WO2010093859A1 (en) 2010-08-19
US20160303057A1 (en) 2016-10-20
CA2781830A1 (en) 2010-08-19
US9463172B2 (en) 2016-10-11
JP5688035B2 (ja) 2015-03-25
EP2395990A1 (en) 2011-12-21
HRP20150120T1 (hr) 2015-05-08
DK2395990T3 (en) 2015-02-23
AU2010213683A1 (en) 2011-09-01
JP2012517480A (ja) 2012-08-02
ES2530047T3 (es) 2015-02-26
CA2781830C (en) 2018-03-27
EP2395990B1 (en) 2015-01-07
SI2395990T1 (sl) 2015-04-30
US20120016036A1 (en) 2012-01-19
PT2395990E (pt) 2015-02-09
US9956189B2 (en) 2018-05-01

Similar Documents

Publication Publication Date Title
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
EP2521724A4 (en) ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES
LT2719708T (lt) Medžiaga ir būdai, skirti su her-3 susijusių ligų gydymui arba prevencijai
EP2424448A4 (en) DEVICES AND METHODS FOR TREATING A PAIN ASSOCIATED WITH AMYGDALECTOMIES
ZA201200263B (en) Compounds and methods for treating influenza
PL2395990T3 (pl) Materiał leczniczy i sposoby leczenia zaburzeń rozwojowych, w tym autyzmu współistniejącego i autyzmu idiopatycznego
IL218763A0 (en) Anti-gcc antibody molecules and related compositions and methods
IL215455A0 (en) Methods and materials for delivering molecules
ZA201303423B (en) Compositions and methods for treating myelofibrosis
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
IL209216A0 (en) Methods for preventing and treating neurodegenerative diseases
EP2416657A4 (en) COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
GB0903299D0 (en) Composition and methods
ZA201202561B (en) Compositions and methods for enhancing cognitive and related functions in animals
ZA201203002B (en) Compositions and methods for treating inflammatory disorders
GB0912468D0 (en) Composition and method
ZA201204262B (en) Composition for improving brain function and method for improving brain function
EP2408906A4 (en) METHODS FOR MODULATING METABOLIC AND CIRCADIAN RYTHMS
EP2512504A4 (en) COMPOSITION AND THERAPEUTIC METHOD
EP2470022A4 (en) COMPOUNDS AND METHODS
EP2448458A4 (en) SYSTEM AND METHODS FOR WIPING MATERIAL
GB0901667D0 (en) Composition and method
EP2278982A4 (en) COMPOSITIONS AND METHODS OF TREATING NEURODEEGENERATIVE ILLNESSES
GB201021822D0 (en) Cleaning composition and method
GB0912714D0 (en) Composition and process